Teva Pharmaceutical Industries Ltd. $TEVA is Ion Asset Management Ltd.’s Largest Position

Ion Asset Management Ltd. reduced its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 85.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,510,000 shares of the company’s stock after selling 32,837,875 shares during the period. Teva Pharmaceutical Industries accounts for about 12.2% of Ion Asset Management Ltd.’s holdings, making the stock its biggest holding. Ion Asset Management Ltd.’s holdings in Teva Pharmaceutical Industries were worth $111,302,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jain Global LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $4,834,000. Farallon Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $100,939,000. Flow Traders U.S. LLC lifted its holdings in Teva Pharmaceutical Industries by 35.4% in the third quarter. Flow Traders U.S. LLC now owns 19,242 shares of the company’s stock valued at $389,000 after acquiring an additional 5,033 shares during the last quarter. Focus Partners Wealth lifted its holdings in Teva Pharmaceutical Industries by 1,058.0% in the third quarter. Focus Partners Wealth now owns 615,737 shares of the company’s stock valued at $12,438,000 after acquiring an additional 562,563 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new position in Teva Pharmaceutical Industries in the third quarter worth approximately $6,248,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 2.6%

Shares of TEVA opened at $28.54 on Monday. The stock has a market capitalization of $32.81 billion, a PE ratio of 23.78, a P/E/G ratio of 9.56 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The company’s 50-day simple moving average is $32.91 and its 200-day simple moving average is $26.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the business posted $0.71 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Placid Jover sold 14,150 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $448,130.50. Following the sale, the insider owned 6,774 shares of the company’s stock, valued at approximately $214,532.58. This represents a 67.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the sale, the director owned 367,600 shares in the company, valued at approximately $11,116,224. The trade was a 17.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 948,499 shares of company stock valued at $30,897,071. Corporate insiders own 0.55% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Scotiabank upped their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Truist Financial increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, The Goldman Sachs Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.